Rare Blood Disorders

Sanofi's Specialty Care business unit of Sanofi, is bringing meaningful advancements to Australians living with haemophilia and other rare blood disorders. The acquisition of Bioverativ and Ablynx created the foundations for our rare blood disorders business and allowed us to develop promising therapies for patients.

Our dedicated Australian team works as a trusted partner to healthcare professionals, governments and patient organisations to secure much needed treatment options and broader access for those living with rare blood disorders.

Our Rare Blood Disorders franchise includes a haemophilia portfolio incorporating extended half life factor products, therapies for cold agglutinin disease, sickle cell disease, and beta thalassemia. We also have the potential to launch several more therapies over the next five years, providing the opportunity to bring new therapies to patients who currently have few options.

Our long-standing partnerships with the rare blood disorder community and local patient organisations are critical to ensuring people living with rare blood disorders are informed and have access to reliable and trusted sources of information. 

As an emerging leader in the rare blood disorder space, we remain steadfast in our commitment to find, research and develop treatments where there is unmet need. We will continue to bring our agility, authenticity and passion to ongoing medical development to support rare blood disorder patients.

Our position as innovators in rare blood disorders is demonstrated through the science underpinning our strong research and development pipeline, with trials planned or underway in cold agglutinin disease, beta thalassemia, sickle cell disease, haemophilia and other rare blood disorders. 

Globally, in collaboration with our distribution partner Sobi, Sanofi Genzyme has pledged to donate up to one billion units of factor replacement therapy
for haemophilia A and B over 10 years. This pledge is helping thousands of patients in over 40 developing countries.